UK health cost body backs Novartis asthma drug in fresh U-turn
Britain’s healthcost-effectivness watchdog NICE said it planned to recommend theuse of Novartis’s severe asthma drug Xolair afterprevaricating for months over whether it should be paid for onthe taxpayer-funded …
More:
UK health cost body backs Novartis asthma drug in fresh U-turn